CDH1 and cancer: In addition, we found that E-cadherin (a migration-associated biomarker) expression was increased after apatinib treatment (Fig. 6F), indicating that apatinib has a great potential for ECCC therapy by inhibiting angiogenesis and cancer cell migration.